Background. Performing a sentinel lymph node biopsy (SLNB) is the standard of care for axillary nodal staging in patients with invasive breast cancer and clinically negative nodes. The procedure provides valuable staging information with few complications when performed by experienced surgeons. However, variation in proficiency exists for this procedure, and a great amount of experience is required to master the technique, especially when faced with challenging cases. The purpose of this paper was to provide a troubleshooting guide for commonly encountered technical difficulties in SLNB, and offer potential solutions so that surgeons can improve their own technical performance from the collective knowledge of experienced specialists in the field. Methods. Information was obtained from a convenience sample of six experienced breast cancer specialists, each actively involved in training surgeons and residents/fellows in SLNB. Each surgeon responded to a structured interview in order to provide salient points of the SLNB procedure. Results. Four of the key opinion surgical specialists provided their perspective using technetium-99 m sulfur colloid, and two shared their experience using blue dye only. Distinct categories of commonly encountered problem scenarios were presented and agreed upon by the panel of surgeons. The responses to each of these scenarios were collected and organized into a troubleshooting guide. Discussion. We present a compilation of 'tips' organized as a troubleshooting guide to be used to guide surgeons of varying levels of experience when encountering technical difficulties with SLNB.
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Sentinel lymph node biopsy (SLNB) is the standard of care for axillary staging in clinically node-negative breast cancer. [1] [2] [3] [4] [5] [6] Prior studies confirm a high degree of variation in the technical proficiency of SLNB. [7] [8] [9] [10] The importance of experience in the accuracy of sentinel node identification was illustrated in a recent multicenter trial. 11 After five training cases, the success rates for individual surgeons identifying a sentinel lymph node (SLN) ranged from 79 to 98 %. Although the false negative rate varied between 0 and 29 % among participating surgeons, proficiency improved with increasing number of cases. Furthermore, Cox et al. showed that surgeons who performed more than six SLNBs per month had lower failure rates than surgeons who performed fewer SLNB procedures. 12 These data are relevant since the majority of breast cancer procedures are performed by surgeons whose practices may not be predominately or exclusively dedicated to breast cancer. [13] [14] [15] Proper surgical technique in SLNB influences outcomes and minimizes the risk of understaging and undertreating patients.
The purpose of this paper is to present a troubleshooting guide of the most commonly encountered problems in Ted A. James and Alex R. Coffman contributed equally as first author.
SLNB and potential solutions created from the combined experience of breast surgeons active in training and evaluating SLNB performance. Our goal is that this troubleshooting guide will help improve the technical performance and success rates of SLNB, especially when presented with technically challenging cases.
DATA GENERATION
A select panel of seven experienced surgeons with recognized expertise in SLNB was contacted for participation in this project. All were active breast cancer surgeons recognized for their expertise in the field and involved in training surgeons in SLNB. All but one of the seven surgeons approached agreed to participate. The participating surgeons reviewed, edited, and agreed upon the technical steps included in the description of the SLNB procedure.
Topics for inclusion in the troubleshooting guide were vetted individually among the group, and consensus was achieved on major areas to be discussed; these topics directly informed the problem scenarios to be addressed. Individual semi-structured interviews were then conducted with each surgeon in order to ascertain their responses and advice pertaining to these scenarios, including solutions to common pitfalls and technical conundrums with SLNB. From the semi-structured interviews, common themes emerged and were included as content in the formal troubleshooting guide. Additional suggestions and tips were included separately in figures detailing further approaches to addressing the problem scenarios.
SENTINEL LYMPH NODE BIOPSY (SLNB) TECHNIQUE
Debate exists regarding the optimal technique for SLNB. Each surgeon needs to find the method that works best for their practice. The literature indicates that sentinel node identification rates can be optimized, and false negative rates can be minimized, by using dual agents as opposed to a single agent, particularly for surgeons with limited experience and in cases where misidentification and false negative rates are known to be higher [e.g. neoadjuvant therapy, prior breast/axillary surgery, and high body mass index (BMI)]. 16, 17 Consideration can also be given to employing lymphoscintigraphy in higher-risk cases. A checklist of key steps for SLNB is presented in Table 1 .
Blue Dye Method
The surgeon typically injects 3-5 mL of blue dye (isosulfan blue or diluted methylene blue) around the tumor periphery, at the palpable edge of the biopsy cavity, or into the subareolar plexus. Subareolar injection may be preferable to avoid staining of the lumpectomy cavity. Intradermal injections of blue dye are avoided to prevent tattooing of the breast or dermal necrosis. The use of isosulfan blue dye is associated with anaphylactic reactions in 0.7-1.1 % of cases. [18] [19] [20] Patients should be screened for make-up allergies (contain blue dye) and prior tattooing as both are associated with an increased risk of allergic reaction. Prophylaxis can be achieved by administering any one of the following: hydrocortisone 100 mg, methylprednisolone 20 mg, dexamethasone 4 mg, diphenhydramine 50 mg, or famotidine 20 mg intravenously. Prophylaxis appears to decrease the severity, but not the incidence, of dye reactions. 18 Neither of the two contributing surgeons who map with blue dye alone utilize prophylaxis given the low reported rate of anaphylaxis. In cases of severe reactions leading to cardiopulmonary collapse, the procedure should be aborted and resumed sometime after the patient is stabilized.
Methylene blue has been proposed as an alternative to isosulfan blue dye, but false negative rates have not been validated with studies including immediate completion Remove any suspicious palpable nodes SLNB sentinel lymph node biopsy, DCIS ductal carcinoma in situ, BMI body mass index, IV intravenous axillary lymph node dissection (ALND), as has been performed for isosulfan blue. Methylene blue is also associated with side effects, including skin necrosis and induration, as well as reports of pulmonary edema and central nervous system reactions in patients who take serotonin-acting medications. [21] [22] [23] Side effects can be potentially minimized by diluting the methylene blue (1:7 dilution; 1.25 mg/mL-0.5 cc of methylene blue mixed with 3.5 cc of normal saline). 24 Despite these issues, methylene blue is widely used and has become the 'de facto' standard in the US because of difficulties obtaining Lymphazurin and the cost of generic 1 % isosulfan blue dye [available from a single manufacturer (Mylan)]. Of note, isosulfan blue can be made by a compounded pharmacy (utilized by one of the authors when Lymphazurin was in short supply).
When performing SLNB using blue dye only it is important not to inject the dye into the tumor itself because the lymphatics can be occluded by tumor. It is also important not to inject into a seroma cavity following an excisional biopsy as the seroma itself does not contain lymphatic channels. Pericavitary injection is preferred to a subareolar technique when upper outer quadrant excisions have already been performed as the scar can obstruct lymphatic drainage from the nipple-areolar complex to the axilla, leading to a failure of mapping. Breast massage can be performed for approximately 5 min to dilate the breast lymphatics. The axillary fascia is entered through an axillary incision. Some surgeons prefer the incision at the inferior border of the axillary hair and extend medially to the edge of the pectoralis major muscle. A careful search is made for blue lymphatic channels leading to blue-stained lymph nodes. All blue lymph nodes and any lymph nodes at the end of a blue lymphatic channel are removed and designated as SLNs. 25 The dye-filled tract is dissected to the first blue lymph node. If possible, the tract is followed proximally to the tail of the breast to ensure that the identified lymph node is the most proximal lymph node and thus the sentinel node. Care must be taken to identify proximal blue nodes because the dye transit time is rapid and blue staining of distal, non-sentinel axillary lymph nodes is not uncommon. 3 Failure to consider the node at the end of a blue lymphatic channel as a sentinel node whether or not the node itself appears blue, and failure to remove the most proximal blue lymph node(s), are the two most common technical errors. Suspicious palpable nodes should also be removed for evaluation as a lymph node replaced with tumor is not likely to take up the localizing dye.
Radiocolloid Method
Radioactive tracer may be injected peritumorally, intradermally, or into the subareolar plexus. There is ongoing debate about the best site for injection. Typically, 0.5 mCi is injected the day of the surgery, or 2.5 mCi is injected the day before as the half-life for technetium-99 m sulfur colloid is 6 h. As with blue dye injection, technetium should not be injected directly into the tumor or into a seroma cavity. The '10 % rule' is a guideline referring to removal of all SLNs with counts over 10 % of the most radioactive node. 26 Surgeons should confirm ex vivo counts to limit falsely positive counts due to in vivo scatter. All nodes that qualify as sentinel nodes should be removed, not just the hottest nodes. A median of two to three SLNs are removed. 27 Suspicious palpable nodes should also be removed for evaluation as a lymph node replaced with tumor is not likely to absorb technetium.
TROUBLESHOOTING GUIDE FOR SLNB
No uptake of radioactive tracer in the axilla This problem is seen most often when the radiotracer is injected into the breast parenchyma alone. The use of a small dermal injection of tracer greatly enhances the activity that reaches the axillary nodes. 28 Some surgeons use the dermal injection technique exclusively as it leads to smaller areas of radioactivity diffusion; however, it should be noted that extra-axillary sites of drainage are rarely identified if only intradermal injections are used. 29 In cases where there is difficulty finding a pre-incision hot spot with a gamma probe, there are some potential remedies. First, be sure the gamma probe is functioning and set to the appropriate settings to maximize the sensitivity of the audio feedback. If there is still difficulty identifying the hot spot, the next step is to inject blue dye to increase the SLN identification rate. Often an SLN can still be identified after an incision has been made and the gamma probe is placed into the axilla. Therefore, proceed with an incision in the axilla and re-evaluate the nodes with the gamma probe. This is especially true in patients with higher BMI. Another technique involves injecting fluid into the site of the technetium injection, using 10-40 mL of sterile saline or local anesthetic. This increases the interstitial pressures, which forces more tracer into the lymphatic channels. It is recommended to perform gentle massage at the injection site, after which the pre-incision hot spot is reassessed with the gamma probe. This process may be repeated as needed if a hot spot is still not identified.
Under circumstances of prior breast/axillary surgery or prior radiation therapy, lymphatic channels may be disrupted, causing alternate drainage pathways to be formed. In these situations, a lymphoscintigraphy can be used preoperatively to identify the appropriate drainage basin. Using dual tracer with radiocolloid and blue dye can also be considered. It is also important to palpate the axilla and resect any palpable abnormal nodes as SLNs.
Intraoperative ultrasound may help identify nodes. If all else fails, the default option is to proceed to ALND or axillary sampling; however, first consider how important the nodal staging information is and the likelihood of nodal positivity. For instance, not identifying an SLN in a T1a low-grade, estrogen receptor (ER) ? , human epidermal growth factor receptor 2 (HER2) tumor in an older woman may not require an ALND. Figure 1 depicts the algorithm for troubleshooting no uptake of radioactive tracer.
Cannot achieve a residual bed count below 10 % of the most radioactive node In the event a surgeon is confronted with a 'high residual bed count' in the axilla, it is important to be sure that all of the 'hottest' nodes have been removed. If the remaining bed counts are uniform, with no 'discreet' areas of greater radioactivity found, and the bed count remains over 10 %, then the surgeon need not remove any other nodes unless they are suspicious by palpation. Data indicate that once four or five SLNs have been resected, the value of additional SLNs is extremely low. 30, 31 Some have reported that taking three SLNs is sufficient, 32 but this has been controversial. 33 Additional details for addressing this situation are presented in Fig. 2 .
Overlap between injection site and axilla (i.e., cannot isolate sentinel node) The problem of overlap of the injection site diffusion zone with the axillary nodes is often an issue with tumors located in the upper outer quadrant and axillary tail of the breast. Utilizing a subareolar injection technique as opposed to a peritumoral injection increases the distance between injection site and axilla, minimizing the potential for overlap. There are an abundance of data in support of this technique. 34 A second potential solution to this problem is to limit the volume of injection as much as possible. For tumors located in the upper outer quadrant/axillary tail, this may be a good situation in which to use small-volume intradermal injections alone as it would be rare for lymphatic drainage in this area to go to extra-axillary sites. The use of small volumes limits the size of the diffusion zone, facilitating identification of the axillary hot spots. Both of these solutions require the surgeon to anticipate the problem prior to injection. Additional potential solutions are illustrated in Fig. 3 .
Radioactive node identified in the internal mammary site Surgeons have debated the utility of dissecting nodes from the internal mammary (IM) chain, given the relative lack of familiarity with the procedure and the associated potential risks (e.g. pneumothorax, bleeding). Current evidence indicates that the prognostic significance of sentinel nodes
Yes
It is uncommon that a change in nodal status will occur with additional lymph node resection 2 Cannot achieve a residual bed count below 10 % of the most radioactive node. * Consideration for future patients. The larger particles in the unfiltered solution are trapped better by the sentinel lymph nodes. Filtered radioactive colloid is best when performing lymphoscintigrams as it quickly identifies the first draining lymph nodes. However, these smaller particles rapidly pass through sentinel nodes and label second and third echelon nodes in the basin. This greatly complicates the surgeon's ability to identify and remove only true sentinel nodes in the IM chain is similar to sentinel nodes in the axilla. 35 Other reports demonstrate the incidence of isolated positive IM nodes (i.e., without concurrent positive axillary SLNs) to be low. 36 Therefore, evidence suggests that the status of the axillary SLNs also reflect the status of the IM nodes in the vast majority of cases. Removal of the IM nodes may not change treatment, particularly if radiation oncologists treat IM nodes in patients with positive axillary nodes. 37 Many of the authors do not routinely evaluate the IM chain with the gamma probe, unless the IM node(s) appears enlarged or abnormal on preoperative imaging [e.g. ultrasound or magnetic resonance imaging (MRI)]. The procedure for identifying and removing sentinel nodes in the IM chain has been previously described. 38 General troubleshooting techniques for blue dye alone The most common cause for a lack of blue dye uptake in the axilla is extensive tumor infiltration. Therefore, the surgeon should always palpate the axilla carefully and remove any palpable suspicious nodes. Incision placement is also critical since the surgeon cannot rely on a gamma probe signal to identify the location of the sentinel node. The incision should be made at the inferior border of the axillary hair and extend medially to the edge of the pectoralis major muscle instead of being centered within the axilla.
In patients with very large breasts, or those over the age of 65 years where failure to map is slightly more frequent, the surgeon can consider increasing the injection volume. 39 A volume of 8-10 cc of blue dye can be used depending on the breast size.
Finally, a common error with the blue dye technique when an SLN is easily identified immediately beneath the incision is failure to actively search for other SLNs. Failure to search for additional blue nodes contributes to a high false negative identification rate. Since the majority of sentinel nodes are in close proximity to one another, it is not necessary to open the entire axilla to search for additional nodes.
Proceed with incision
• Recheck axilla with gamma probe • Advance gamma probe into axillary fat to increase additional distance FIG. 3 Overlap between injection site and axilla (i.e., cannot isolate the sentinel lymph node). Note this problem may be anticipated for tumors in the upper outer quadrant and avoided by using a subareolar injection or by limiting the injection volume DISCUSSION Sentinel lymph node biopsy has gained widespread acceptance as the primary means of axillary staging for patients with clinically node-negative invasive breast cancer. Many surgeons have obtained appropriate training and experience in the procedure and have reached an ideal level of proficiency performing the technique. However, some variation in technical performance remains, and practical guidance can help success rates of SLNB, especially when first commencing with the procedure in practice or when encountering unusual or difficult circumstances.
Troubleshooting has long been used in industries such as engineering, computer science, and mechanics. The application of this process to a surgical procedure is a relatively novel endeavor. The techniques outlined in this guide offer a concise and practical approach to addressing problems with SLNB (compiling 'tips' learned through years of collective experience). The information presented is intended to provide a logical, systematic approach to problem solving, thereby enhancing the success rate of SLNB.
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